Plains Ventures

08/26/2026

We asked our team: Can you share an example of how the Plains Ventures process has impacted an investment decision?

Justin Wilson, President & Managing Director, told us:
"In venture, we see dozens, sometimes hundreds, of opportunities for every one that's actually a fit. That doesn't mean most of them are bad companies. It usually just means the stage, valuation, or inflection point doesn't match our fund's mandate or return needs.

Even when we don't invest, the process itself can be valuable. Founders regularly tell us our diligence surfaced issues they didn't know existed, sometimes something minor and easy to fix, like discovering they aren't authorized to do business in the state they're operating in (more common than you'd think). Other times it's something more serious. Almost none of it is intentional; usually it's just an oversight that never got caught."

Not every deal ends in an investment, but it can still end in a better business.

08/18/2026

From first meeting to long-term partnership, check out this look inside the Plains Ventures process.

07/28/2026

We're proud to see KiZE featured in Live In Oklahoma, the state's campaign to attract top business and talent to Oklahoma.

KiZE has grown from an OKC startup to Costco shelves and beyond, proof that purpose-built businesses can scale right here in the heartland, all while creating second-chance jobs and giving back to the community.

Congrats to Jeff Ragan and the whole KiZE team!

Watch:

From a four-foot table at the local farmers market to shelves natio...

07/13/2026

Congrats to our portfolio company Linear Health Sciences on a new partnership with NIPRO Corporation, bringing Linear's Orchid Safety Release Valve to the Japanese market starting July 22, 2026.

It's Linear's first major step into global markets, proof that Oklahoma-born innovation can compete on the world stage. Exactly the kind of trajectory we love backing.

https://ow.ly/51ou50Zn5Sz

06/25/2026

Catching Alzheimer's before symptoms appear. That's the goal, and our portfolio company Moleculera Biosciences is closer to making it a reality.

Moleculera and partner Lunai Bioworks are developing a first-of-its-kind blood test to identify immune-mediated Alzheimer's disease at the earliest possible stage, before patients even know something is wrong. The alliance combines Moleculera's biomarker science with the AI-driven analytics platform from Lunai's subsidiary, BioSymetrics.

The partnership received a significant boost: Lunai closed a $20M transaction last year to acquire blood-brain barrier delivery technology and Alzheimer's CNS drug assets, directly advancing the pipeline the two companies are building together.

Early detection changes everything. Proud to support the team working to make it possible.

06/18/2026

Portfolio milestone: Progentec Diagnostics.

Progentec published peer-reviewed research in Lupus Science & Medicine and secured an Oklahoma Center for the Advancement of Science and Technology (OCAST) Industry Innovation Grant — both major milestones validating the science and commercial potential behind their lupus classification risk blood test.

The L-CRI (Lupus Classification Risk Immune Index) represents a meaningful advancement in early diagnostics, with the potential to identify at-risk patients long before clinical disease classification.

Scientific validation + non-dilutive funding = strong momentum. We're proud to back the team at Progentec.

06/15/2026

Specialist funds now command 72% of LP capital raised in 2025–2026 according to PitchBook LPs are concentrating around focused strategies, not generalists. We have: one geography, one focus, one thesis. The most undercapitalized early-stage market in the country. plainsvc.com

06/09/2026

Proud of Kize Concepts Founder & CEO Jeff Ragan on being named a finalist for the EY Entrepreneur of the Year Award.

Jeff built KiZE into a better-for-you energy bar brand rooted in real, simple ingredients, and a business that creates jobs for people who need them most.

Being named a finalist is a well-deserved honor. Congrats, Jeff!

06/04/2026

In venture, cycles change, fundamentals don’t.

As we move deeper into 2026, we’re staying anchored to the same approach that’s guided us across market turns. Less noise. More time on the ground.

A few things we’re watching:
• Founder efficiency is no longer optional, it’s a differentiator
• Clear paths to distribution are beating “feature-first” roadmaps
• The best companies still get funded… they just get funded on proof, not hype

If you’re building something durable between the coasts, we’d love to see it. plainsvc.com

06/02/2026

The Q1 2026 VC numbers look incredible on the surface.

$267 billion in deal value. $347 billion in exits. Record highs.

Then you look closer.

Remove the five largest deals — and deal value drops by 73%.
Remove the five largest exits — and exit value drops by 87%.

The headline market is being written by a handful of companies. For everyone else, the environment hasn't changed much from 2025: tight liquidity, higher proof requirements, and capital that's harder to access than the top-line numbers suggest.

This is exactly the market Plains Ventures was built for.

We invest in the founders building real businesses in the places the headline market has forgotten. Oklahoma. The region. The middle of the country.

The concentration at the top is real. So is the opportunity beneath it. plainsvc.com